In This Article:
GEMS(TM) Rhythm AI Clearance will Address Event, Holter and Long-Term Continuous ECG Monitoring Needs for Remote Patient Monitoring in Canada
Toronto, Ontario--(Newsfile Corp. - September 30, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software and hardware solutions, is pleased to announce it has received Health Canada clearance of its GEMS™ Rhythm ECG artificial intelligence (AI) software for the automated detection of multiple arrhythmias and morphology abnormalities.
The GEMS Rhythm arrhythmia and morphology abnormality AI detection will include atrial fibrillation, prolonged QT and QTc intervals, tachycardia/bradycardia/pause, average heart rate, PQ and QRS intervals, identification of patterns of different heart beats such as PACs, PVCs, bigeminy and trigemini, as well as estimation of the heart rate variability.
The clearance of the GEMS™ Rhythm technology is a critical milestone in the Company's product road map to develop its GEMS™ software into an all-in-one, device-agnostic, ECG software solution. GEMS™ Rhythm will first be offered with the Company's GEMS™ FLEX ECG software to support automated analysis of one to three leads of ECG data acquired through event recorders worn for up to 30 days. Additionally, GEMS™ Rhythm will automatically review ECGs from its consumer HeartCheck™ ECG products.
In the next phases of software releases, GEMS™ Rhythm will be used with the GEMS™ Holter and GEMS™ LTCM solutions (in development) to perform continuous monitoring of ECGs over durations of 24 hours to 14 days, with near real-time event triggering throughout the monitoring period. CardioComm's all-in-one GEMS™ solutions for Event, Holter/Event, and LTCM will provide hospitals, physician groups, and commercial laboratories with ultimate flexibility to provide customized patient care in a fully integrated, device-agnostic software solution.
GEMS™ Rhythm, GEMS Holter, and GEMS™ LTCM will join CardioComm's growing product lines, including the HeartCheckTM branded home ECG devices and the Body-by-GEMSTM multiple bio-signal monitoring solutions.
CardioComm is pleased to confirm that research and development support for this GEMS™ Rhythm project was provided in part through an NRC Industrial Research Assistance Program (NRC-IRAP) contribution agreement of up to $150,000.
To learn more about CardioComm's products and for further updates please visit the Company's website at www.cardiocommsolutions.com.